ClinicalTrials.gg
TerminatedNCT05883449LuminICE-203Updated Aug 20, 2025Results posted

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

A Phase 2 interventional study of AFM13 and AB-101 in Relapsed or Refractory Hodgkin Lymphoma and Peripheral T Cell Lymphoma, sponsored by Affimed GmbH. Terminated at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Primary conditionHodgkin DiseaseRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hodgkin Disease
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Hodgkin Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Affimed GmbH · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 970 studies in Hodgkin Disease with a site in United States — 75 open to participants now, 142 under way, 6 of them phase 3. Hodgkin Disease · United States.

Enrollment
503rd of 818
25 · median 35
Started
2023
with 11 others
Phase 2
346 of 970
30 open now
Registered
924th of 970
by date

Among the 970 studies in Hodgkin Disease with a site in United States, this one is the 503rd largest by enrollment of the 818 interventional ones that give a count, is one of 12 that started in 2023, is one of 346 in phase 2, and was the 924th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

75 of the 970 studies in Hodgkin Disease with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 970 studies in Hodgkin Disease with a site in United States, or all of them as a file.
02

Study summary

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

Read the detailed description

The study will start with a safety run-in exploring AFM13/AB-101 combination treatment in subjects with classical HL. Two dose levels of AFM13 and AB-101, respectively, will be tested in 4 cohorts. Cohort 1 and 2 will enroll in parallel. Enrolment into Cohort 3 and 4 will start only if the combination treatment has been well tolerated.

Following the safety run-in observation period, a thorough risk-benefit analysis will be performed to determine 2 of the 4 cohorts/dose levels that will be further evaluated in the main part of the study which will also include subjects with classical HL and will follow a Simon two-stage design.

An additional exploratory cohort (Cohort 5) will enroll subjects with select CD30-positive PTCL subtypes after completion of the safety run-in.

All subjects will be treated with AFM13/AB-101 for a maximum of 3 cycles (cycle length is 48-days).

03

Conditions studied

  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma

Browse trials for

04

In context

Hodgkin Disease Reclassified

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

This study's enrollment of 25 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.

Browse Hodgkin Disease studies →

Lead sponsor

Affimed GmbH is the lead sponsor of 9 studies on the registry; none are open to participants now.

Compared within Hodgkin Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of FDG-avid classical HL OR select subtypes of FDG-avid CD30-positive relapsed or refractory PTCL
  • For subjects with R/R PTCL a pre-enrollment tumor positive for CD30 locally assessed by Ber-H2 targeted immunohistochemistry at ≥1% is mandatory (PTCL subtypes: PTCL-NOS, Angioimmunoblastic T-cell lymphoma, ALCL, anaplastic lymphoma kinase (ALK)-positive, ALCL, ALK-negative)
  • Subjects with R/R classical HL must have received at least two including one prior line of combination chemotherapy. Prior therapy must also have included brentuximab vedotin and a PD1 check point inhibitor.
  • Subjects with R/R PTCL must have received at least one prior line of combination chemotherapy. Subjects with ALCL subtype of PTCL must have received or been intolerant to brentuximab vedotin.
  • Subjects with R/R classical HL AND R/R PTCL: Prior is permitted if completed at least 3 months prior to the first dose of study treatment. Prior allogeneic stem cell transplantation will be permitted if completed at least 1 year from study enrollment and there are no signs or symptoms of . Prior CAR-T therapy is permitted if last CAR-T dose completed at least 6 months prior to the first dose of study treatment.
  • Ability to understand and sign the ICF

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) involvement (untreated or uncontrolled parenchymal or positive cytology of cerebrospinal fluid)
  • Previous treatment with AFM13 or CBNK cells
  • History of a solid organ allograft, or an inflammatory or disease likely to be exacerbated by IL-2 (including subjects requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease that may require systemic or agents
  • Treatment with any therapeutic mAb or immunosuppressive medications
  • Known active or C defined per protocol
  • Active Infection
  • History of any other systemic , unless previously treated with curative intent and the subject has been disease free for 2 years or longer
  • Active acute or chronic graft vs. host disease () or GVHD requiring immunosuppressive treatment, central nervous system (CNS) dysfunction
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Safety run-in in Hodgkin Lymphoma

    4 safety run-in cohorts: * Cohort 1: 200 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15) * Cohort 2: 300 mg AFM13 + AB-101 (2 × 10e9 cells on Day 1, Day 8, Day 15) * Cohort 3: 200 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15) * Cohort 4: 300 mg AFM13 + AB-101 (4 × 10e9 cells on Day 1; 2 × 10e9 cells on Day 8, Day 15)

    Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2

  • Experimental
    Dose Level A in Hodgkin Lymphoma

    Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level A (selected from cohort 1-4 of Safety run-in)

    Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2

  • Experimental
    Dose Level B in Hodgkin Lymphoma

    Randomized Simon 2-stage design in Hodgkin Lymphoma Dose Level B (selected from cohort 1-4 of Safety run-in)

    Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2

  • Experimental
    Exploratory: AFM13 + AB-101 on CD30-positive PTCL

    AFM13 + AB-101 on select CD30-positive PTCL subtypes (Dose Level A or B)

    Drug: AFM13 · Drug: AB-101 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Interleukin-2

Interventions

  • DrugAFM13

    anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

  • DrugAB-101

    NK cell therapy, intravenous infusion

  • Lymphodepleting chemotherapy, intravenous infusion

  • Lymphodepleting chemotherapy, intravenous infusion

  • Immune cytokine, subcutaneously

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Independent Radiology Committee

    Best ORR (complete response (CR) + partial response \[PR\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification. A participant will be assumed as a responder if he/she achieves complete or partial response at any postbaseline visit.

    Time frame: Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.

Secondary outcomes

  1. Duration of Response by Independent Radiology Committee

    Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed by Independent Radiology Committee.

    Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)

  2. Complete Response Rate (CRR) by Independent Radiology Committee

    Complete Response Rate based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.

    Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)

  3. ORR by Investigator Based on PET-CT as Assessed by the Lugano Classification

    ORR (CR + PR) by Investigator based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification

    Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)

  4. Duration of Response by Investigator

    Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed locally by the Investigator.

    Time frame: Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)

  5. Incidence of Subjects Receiving Subsequent Transplant

    The number of subjects receiving subsequent transplant will be assessed and summarized by percentage rates

    Time frame: Throughout study completion (up to 20 months)

  6. Frequency of Subjects With Study Drug Related TEAEs

    The number of subjects with study-drug related (AFM13 or AB-101) treatment-emergent adverse events (TEAEs)

    Time frame: From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)

  7. Frequency of Subjects With Serious Treatment Emergent Adverse Events

    The number of subjects who had serious treatment emergent adverse events.

    Time frame: From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)

  8. Frequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM13

    The number of subjects developing anti-drug antibodies (ADAs) against AFM13

    Time frame: During treatment cycles (up to 6 months)

  9. Progression-free Survival (PFS) by Independent Radiology Committee

    Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until progressive disease (PD). Subjects who started a new anti-lymphoma therapy prior to a documented progressive disease were censored at the last disease assessment prior to initiation of new anti-lymphoma therapy. Subjects who discontinued the study before the first assessment of progressive disease or death were censored at their last disease assessment.

    Time frame: From the first treatment received until the first progression disease assessed by IRC or death.

  10. Overall Survival

    Overall Survival (OS) was defined as (date of death - date of first dose)/30.4375. Patients alive at the end of study will be censored on the last date of observation.

    Time frame: From the first treatment received until the death.

08

Results

Posted Aug 20, 2025
Limitations and caveats
The decision to terminate this study was based solely on the financial situation of the company and was not related to the safety or efficacy. Given this limitation, the results of the time to event endpoints are premature.

Participant flow

Participant flow — Overall Study
MilestoneSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Started6766
Completed1363
Not completed5403

Outcome measures

PrimaryObjective Response Rate (ORR) by Independent Radiology Committee

Best ORR (complete response (CR) + partial response \[PR\]) by Independent Radiology Committee (IRC) based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification. A participant will be assumed as a responder if he/she achieves complete or partial response at any postbaseline visit.

Time frame:
Disease assessments were conducted on Day 43 (+- 3 days) of each cycle. All subjects were treated for a maximum of 3 cycles.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) by Independent Radiology Committee
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Objective Response Rate (ORR) by Independent Radiology Committee5565
SecondaryDuration of Response by Independent Radiology Committee

Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed by Independent Radiology Committee.

Time frame:
Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Reported as:
Median · months
Duration of Response by Independent Radiology Committee
monthsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Duration of Response by Independent Radiology Committee4.90 (2.20 to NA)NA (NA to NA)NA (NA to NA)6.97 (2.30 to NA)
SecondaryComplete Response Rate (CRR) by Independent Radiology Committee

Complete Response Rate based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification.

Time frame:
Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Reported as:
Count of participants · Participants
Complete Response Rate (CRR) by Independent Radiology Committee
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Complete Response Rate (CRR) by Independent Radiology Committee4343
SecondaryORR by Investigator Based on PET-CT as Assessed by the Lugano Classification

ORR (CR + PR) by Investigator based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification

Time frame:
Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Reported as:
Count of participants · Participants
ORR by Investigator Based on PET-CT as Assessed by the Lugano Classification
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
ORR by Investigator Based on PET-CT as Assessed by the Lugano Classification4566
SecondaryDuration of Response by Investigator

Duration of response (DOR) defined as time from first assessment of PR or CR to the first assessment of progressive disease/death. Response based on positron emission tomography-computed tomography (PET-CT) as assessed by the Lugano classification assessed locally by the Investigator.

Time frame:
Tumor assessment performed every 6 weeks for 3 cycles, if no disease progression on completion of treatment, then every 3 months for the first 12 months and then every 6 months (up to 20 months)
Reported as:
Median · months
Duration of Response by Investigator
monthsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Duration of Response by Investigator3.86 (2.20 to NA)6.28 (2.10 to NA)NA (NA to NA)4.65 (2.30 to NA)
SecondaryIncidence of Subjects Receiving Subsequent Transplant

The number of subjects receiving subsequent transplant will be assessed and summarized by percentage rates

Time frame:
Throughout study completion (up to 20 months)
Reported as:
Count of participants · Participants
Incidence of Subjects Receiving Subsequent Transplant
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Incidence of Subjects Receiving Subsequent Transplant1201
SecondaryFrequency of Subjects With Study Drug Related TEAEs

The number of subjects with study-drug related (AFM13 or AB-101) treatment-emergent adverse events (TEAEs)

Time frame:
From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)
Reported as:
Count of participants · Participants
Frequency of Subjects With Study Drug Related TEAEs
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Frequency of Subjects With Study Drug Related TEAEs5455
SecondaryFrequency of Subjects With Serious Treatment Emergent Adverse Events

The number of subjects who had serious treatment emergent adverse events.

Time frame:
From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months)
Reported as:
Count of participants · Participants
Frequency of Subjects With Serious Treatment Emergent Adverse Events
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Frequency of Subjects With Serious Treatment Emergent Adverse Events2545
SecondaryFrequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM13

The number of subjects developing anti-drug antibodies (ADAs) against AFM13

Time frame:
During treatment cycles (up to 6 months)
Reported as:
Count of participants · Participants
Frequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM13
ParticipantsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Frequency of Subjects Developing Anti-drug Antibodies (ADAs) Against AFM132121
SecondaryProgression-free Survival (PFS) by Independent Radiology Committee

Progression-free survival (PFS) defined as time from first treatment (AFM13/AB-101) received until progressive disease (PD). Subjects who started a new anti-lymphoma therapy prior to a documented progressive disease were censored at the last disease assessment prior to initiation of new anti-lymphoma therapy. Subjects who discontinued the study before the first assessment of progressive disease or death were censored at their last disease assessment.

Time frame:
From the first treatment received until the first progression disease assessed by IRC or death.
Reported as:
Median · months
Progression-free Survival (PFS) by Independent Radiology Committee
monthsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Progression-free Survival (PFS) by Independent Radiology Committee4.17 (1.45 to NA)7.66 (1.28 to NA)NA (NA to NA)8.28 (1.35 to NA)
SecondaryOverall Survival

Overall Survival (OS) was defined as (date of death - date of first dose)/30.4375. Patients alive at the end of study will be censored on the last date of observation.

Time frame:
From the first treatment received until the death.
Reported as:
Median · months
Overall Survival
monthsSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Overall SurvivalNA (NA to NA)12.25 (3.48 to NA)9.72 (NA to NA)NA (NA to NA)

Adverse events

Collected over From the time of first protocol-specific intervention until 30 days after the last administration (up to 20 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety run-in Cohort 11/6 (16.7%)2/6 (33.3%)6/6 (100%)
Safety run-in Cohort 24/7 (57.1%)5/7 (71.4%)7/7 (100%)
Safety run-in Cohort 31/6 (16.7%)4/6 (66.7%)6/6 (100%)
Safety run-in Cohort 40/6 (0%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
Infusion Related ReactionInjury, poisoning and procedural complications1/61/70/62/6
PneumoniaInfections and infestations1/60/70/61/6
Cytomegalovirus OesophagitisInfections and infestations1/60/70/60/6
Cytomegalovirus ViraemiaInfections and infestations1/60/70/60/6
UrosepsisInfections and infestations0/60/71/60/6
Cytokine Release SyndromeImmune system disorders1/61/71/61/6
AnaemiaBlood and lymphatic system disorders0/61/70/61/6
PyrexiaGeneral disorders0/61/70/61/6
MalaiseGeneral disorders1/60/70/60/6
HyperglycaemiaMetabolism and nutrition disorders0/60/71/60/6
Most frequent other events
Showing 10 of 138
Most frequent other events
EventSafety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4
NauseaGastrointestinal disorders5/66/74/64/6
ConstipationGastrointestinal disorders4/65/73/62/6
VomitingGastrointestinal disorders4/65/72/61/6
FatigueGeneral disorders4/65/74/61/6
PyrexiaGastrointestinal disorders4/65/70/62/6
DiarrhoeaGastrointestinal disorders4/61/73/60/6
Infusion Related ReactionInjury, poisoning and procedural complications2/64/74/62/6
HeadacheNervous system disorders3/63/74/61/6
HypokalaemiaMetabolism and nutrition disorders4/62/71/60/6
AnaemiaBlood and lymphatic system disorders4/63/71/62/6

Baseline characteristics

Safety Analysis Set

Age, Continuous
Age, Continuous(years)Safety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4Total
Mean50.5 ± 20.6843.6 ± 19.2154.7 ± 14.6146.0 ± 19.848.5 ± 18.07
Sex: Female, Male
Sex: Female, Male(Participants)Safety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4Total
Female364417
Male31228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Safety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00112
White675523
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Safety run-in Cohort 1Safety run-in Cohort 2Safety run-in Cohort 3Safety run-in Cohort 4Total
United States676625
09

Study locations

15 sites
  • O'Neal Comprehensive Cancer Center at UAB
    Birmingham, Alabama 35294, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UC Irvine Health
    Orange, California 92868, United States
  • Sarah Cannon Research Institute
    Denver, Colorado 80218, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Beth Israel Deaconess Medical
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Masonic Cancer Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • UNC Immunotherapy Team, University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2024, 12 months.

Results were first posted in Aug 2025, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
Jun 1, 2023
StartActual
Oct 10, 2023
Primary completionActual
Nov 7, 2024
CompletionActual
Jun 13, 2025
Results first posted
Aug 20, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05883449
Lead sponsor
Affimed GmbH
Collaborators
Artiva Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Oct 10, 2023
Primary completion
Nov 7, 2024
Completion
Jun 13, 2025
Results posted
Aug 20, 2025
Last update
Aug 20, 2025

Study contacts

Wunderle Lydia, MD
study director · Affimed Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AFM13 · AB-101

Start the discussion